Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arrowhead Misfires: Abandons Clinical Programs, But Keeps Amgen Deal

Executive Summary

Arrowhead Pharmaceuticals shifts focus to subcutaneous platform after abandoning lead hepatitis B program and related products due to toxicity concerns, resolving to lay off 30% of staff.


Related Content

RNA Therapeutics Near A Tipping Point, Says Silence’s CEO
Stockwatch: Bluebird, Arrowhead And Short Memories
Arrowhead Tumbles As FDA Puts A Clinical Hold On Novel HBV Therapy Trial
Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration
FDA lifts partial clinical hold on Arrowhead drug


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts